Cleared Traditional

K813261 - RIAGEN PAP RIA

K813261 is the FDA 510(k) clearance for RIAGEN PAP RIA by Biogenex Laboratories. It is a Class 2 Chemistry device (product code JFH) cleared through the Traditional 510(k) pathway after a 27-day FDA review.

K813261 · Biogenex Laboratories · Chemistry device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Dec 1981
Decision
27d
Days
Class 2
Risk

K813261 is an FDA 510(k) clearance for the RIAGEN PAP RIA. Classified as Acid Phosphatase (prostatic), Tartrate Inhibited (product code JFH), Class II - Special Controls.

Submitted by Biogenex Laboratories (Mchenry, US). The FDA issued a Cleared decision on December 17, 1981 after a review of 27 days - a notably fast clearance cycle.

This device falls under the Chemistry FDA review panel, regulated under 21 CFR 862.1020 - the FDA in vitro diagnostics and chemistry framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Biogenex Laboratories devices

Submission Details

510(k) Number K813261 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received November 20, 1981
Decision Date December 17, 1981
Days to Decision 27 days
Submission Type Traditional
Review Panel Chemistry (CH)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
61d faster than avg
Panel avg: 88d · This submission: 27d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code JFH Acid Phosphatase (prostatic), Tartrate Inhibited
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.1020
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Chemistry devices follow this clearance model.

Regulatory Peers - JFH Acid Phosphatase (prostatic), Tartrate Inhibited

All 29
Devices cleared under the same product code (JFH) and FDA review panel - the closest regulatory comparables to K813261.
ORTHO*PAP-IA ENDOGENOUS ENZYME IMMUNO
K831670 · Ortho Diagnostic Systems, Inc. · Aug 1983
CORDIA PAP
K831105 · Cordis Corp. · May 1983
ABBOTT PAP-EIA
K812925 · Abbott Laboratories · Jan 1982
TANDEM PAP KIT - (PARTS I & II)
K811959 · Hybritech, Inc. · Sep 1981
PROSTATIC ACID PHOSPHATASE RADIOIMM. KIT
K811274 · Bd Becton Dickinson Vacutainer Systems Preanalytic · May 1981
PROSTATIC ACID PHOSPHATASE (PAP) RDA KIT
K811169 · Amersham Corp. · May 1981